




RealRate

MEDICINAL PRODUCTS 2021

Navidea Biopharmaceuticals Inc.
Rank 46 of 52





RealRate

MEDICINAL PRODUCTS 2021

Navidea Biopharmaceuticals Inc. Rank 46 of 52



The relative strengths and weaknesses of Navidea Biopharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Navidea Biopharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 33% points. The greatest weakness of Navidea Biopharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -133%, being 78% points below the market average of -55%.

Input Variable	Value in 1000 USD
Assets, Current	6,528
Assets, Non-Current	477
General and Administrative Expense	6,696
Goodwill	620
Liabilities, Current	4,715
Liabilities, Non-Current	296
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	700
Other Net Income	-11
Other Revenues	915
Property, Plant and Equipment, Net	132
Research and Development	4,930

Output Variable	Value in 1000 USD
Liabilities	5,711
Assets	7,758
Expenses	11,626
Revenues	915
Stockholders Equity	2,047
Net Income	-10,722
Comprehensive Net Income	-10,722
Economic Capital Ratio	-133%